Washington University School of Medicine in St. Louis | Strategic Alliance Partners

Latest from Washington University School of Medicine in St. Louis


Phase 1 Trial Set to Explore Efficacy and Safety of KB-0742 in Solid Tumors

June 16, 2023

Brian Van Tine, MD, PhD, discusses key considerations for understanding the biology of MYC, the rationale for the phase 1 study of KB-0742 in MYC-amplified or -overexpressed relapsed or refractory solid tumors, and patient characteristics that may signal their eligibility for participation in this trial.

Dr Van Tine on Investigating Cabozantinib With PD-1 and CTLA-4 Inhibition in Sarcoma

June 09, 2023

Brian A. Van Tine, MD, PhD, discusses the rationale for launching a randomized phase 2 trial investigating cabozantinib combined with nivolumab and ipilimumab vs cabozantinib alone in metastatic soft tissue sarcoma and discusses key findings from the trial.

ABBV-011 Showcases Early Tolerability, Antitumor Activity in Small Cell Lung Cancer

June 05, 2023

The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.

Jumping Genes in Cancer Cells Open Door to New Immunotherapies

May 05, 2023

Research from Washington University School of Medicine in St. Louis suggests that transposable elements in various cancers potentially may be used to direct novel immunotherapies to tumors that don’t typically respond to immune-based treatments.

Siteman Cancer Center Names New Deputy Director Among Other Leadership Appointments

May 02, 2023

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis announces several leadership changes, including a new Deputy Director, Associate Directors of Translational Research and Shared Resources, and a Deputy Associate Director of Shared Resources.

Dr Ademuyiwa on the Sequencing of First-line CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

April 20, 2023

Foluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor (HR)–positive, HER2-negative breast cancer based on updated efficacy and safety data.

Dr González-González on DDR Pathway Inhibition in HER2-low TNBC Breast Cancer Models

April 12, 2023

Adrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.

Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer Models

April 12, 2023

Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.

Two-Pronged Immunotherapy Eliminates Metastatic Breast Cancer in Mice

April 07, 2023

Researchers at Washington University School of Medicine in St. Louis have identified a way to treat the area surrounding breast tumors that have spread to bone so that such tumors become vulnerable to attack by the body’s immune system.